A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control

Table 2 Correlation between glycaemic control, measured as haemoglobin (Hb)A1c, plasma glucose levels and study endpoints in type 1 diabetes patients at baseline and when receiving aspirin 75 mg or 300 mg once daily (OD)

Parameter	Correlation with HbA1c						Correlation with plasma glucose
	Baseline		75 mg OD		300 mg OD		Baseline		75 mg OD		300 mg OD
	R	p	R	p	R	p	R	p	R	p	R	p
Platelet aggregation
AA 1 mmol/L	0.24	0.11	0.17	0.28	0.13	0.41	0.058	0.71	0.12	0.47	0.054	0.73
Collagen 2 µg/mL	0.095	0.55	0.25	0.11	0.36	0.019	− 0.13	0.42	0.032	0.84	0.096	0.54
Collagen 16 µg/mL	0.076	0.62	− 0.015	0.93	0.23	0.14	0.15	0.33	− 0.06	0.71	0.068	0.67
Fibrin clot turbidimetry
Lag time (s)	0.17	0.27	0.0032	0.98	− 0.11	0.48	0.36	0.019	0.044	0.79	0.046	0.77
Final clot turbidity (AU)	0.57	< 0.0001	0.54	0.00021	0.45	0.0033	0.2	0.19	0.31	0.05	0.24	0.12
Lysis time (s)	0.54	0.00015	0.38	0.011	0.4	0.01	0.046	0.77	0.059	0.71	0.21	0.17
Fibrinogen and C3
Fibrinogen (g/L)	0.48	0.00099	0.32	0.034	0.48	0.0017	0.35	0.022	0.09	0.57	0.18	0.24
C3 (g/L)	0.24	0.12	0.21	0.18	0.094	0.56	0.011	0.94	0.097	0.55	− 0.24	0.13

Data generated using the Pearson method. Values in bold indicate those associated with a p value < 0.05

ISSN: 1475-2840